[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpECbe7Ja9YOjasxeVGK8cIcOFfxuVfweoDS6YhVD0kk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Creighton University",[4],126,false,5,21193,0,87,[13,16,19,21,23,26,28,30],{"name":14,"count":15},"Vitamin D Deficiency",8,{"name":17,"count":18},"Osteoporosis",7,{"name":20,"count":8},"Atrial Fibrillation",{"name":22,"count":8},"Asthma",{"name":24,"count":25},"Maternal-Fetal Relations",4,{"name":27,"count":25},"Hypertension",{"name":29,"count":25},"Post-Traumatic Stress Disorder",{"name":31,"count":32},"Schizophrenia",3,[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,91,126,161,196,230,252,278,303,321,339,357,375,393,411,429,447,465,483,501,525,549,576,602,627,645,671,697,715,733,756,780,798,822,845,869,892,918,936,954,979,1004,1022,1046,1074,1097,1119,1143,1167,1185,1209,1234,1258,1276,1298,1320],{"intervention":43,"totalTrials":44,"cells":45},"Metoprolol tartrate",2,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":89},{"trials":47,"activeCount":10},[],{"trials":49,"activeCount":10},[],{"trials":51,"activeCount":10},[],{"trials":53,"activeCount":10},[],{"trials":55,"activeCount":10},[56,78],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"NCT00661895","Black Education and Treatment of Hypertension (BEAT HTN)","COMPLETED",[39],"2009-08","2009-11","2005-08",99,[27],[67,68,69,70,43,71,72,73,74,75,76,77],"Hydrochlorothiazide","Lisinopril","Lisinopril and Hydrochlorothiazide","Nifedipine XL","Atenolol","Valsartan","Doxazosin","Clonidine","Hydralazine","Metoprolol succinate","Amlodipine",{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":87},"NCT02251509","Rate Control in Atrial Fibrillation","UNKNOWN",[39],"2017-09","2016-12",20,[20],[88,43],"Carvedilol",{"trials":90,"activeCount":10},[],{"intervention":92,"totalTrials":44,"cells":93},"Omalizumab",{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":124},{"trials":95,"activeCount":10},[],{"trials":97,"activeCount":10},[],{"trials":99,"activeCount":10},[],{"trials":101,"activeCount":10},[],{"trials":103,"activeCount":10},[104,113],{"nctId":105,"briefTitle":106,"status":59,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT00657891","The Effect of Xolair (Omalizumab) on Allergy Blood Cells",[39],"2007-10","2007-03",49,[22],[92],{"nctId":114,"briefTitle":115,"status":81,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT00208234","Effect of Xolair on Airway Hyperresponsiveness",[39],"2011-09","2004-01",22,[121],"Allergic Asthma",[92,123],"omalizumab",{"trials":125,"activeCount":10},[],{"intervention":127,"totalTrials":44,"cells":128},"Risperidone",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":159},{"trials":130,"activeCount":10},[],{"trials":132,"activeCount":10},[],{"trials":134,"activeCount":10},[],{"trials":136,"activeCount":10},[],{"trials":138,"activeCount":10},[139,147],{"nctId":140,"briefTitle":141,"status":59,"phases":142,"completion":143,"start":144,"enrollment":85,"conditions":145,"interventions":146},"NCT00208182","Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma",[39],"2004-08","2001-07",[29],[127],{"nctId":148,"briefTitle":149,"status":59,"phases":150,"completion":151,"start":152,"enrollment":85,"conditions":153,"interventions":157},"NCT00208143","Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia",[39],"2005-12","2003-11",[31,154,155,156],"Schizoaffective Disorder","Substance Abuse","Substance Dependence",[158,127],"Quetiapine",{"trials":160,"activeCount":10},[],{"intervention":162,"totalTrials":44,"cells":163},"Xolair",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":194},{"trials":165,"activeCount":10},[],{"trials":167,"activeCount":10},[],{"trials":169,"activeCount":10},[],{"trials":171,"activeCount":10},[],{"trials":173,"activeCount":10},[174,184],{"nctId":175,"briefTitle":176,"status":59,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT00139152","Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair",[39],"2009-12","2005-09",65,[182],"Lung Disease",[162],{"nctId":185,"briefTitle":186,"status":81,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT00673218","The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils",[39],"2012-11","2007-06",25,[192],"Allergy",[162],{"trials":195,"activeCount":10},[],{"intervention":197,"totalTrials":44,"cells":198},"Chlorthalidone 12.5 mg",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":228},{"trials":200,"activeCount":10},[],{"trials":202,"activeCount":10},[],{"trials":204,"activeCount":10},[],{"trials":206,"activeCount":10},[],{"trials":208,"activeCount":10},[209,219],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":10,"conditions":216,"interventions":217},"NCT01822860","Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function","WITHDRAWN",[39],"2015-02","2013-03",[27],[197,218],"Hydrochlorothiazide 25 mg",{"nctId":220,"briefTitle":221,"status":81,"phases":222,"primaryCompletion":84,"completion":84,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT02100462","Chlorthalidone and HCTZ Impacts on Platelet Activation",[39],"2014-03",30,[27],[197,218,227],"Aspirin 81 mg",{"trials":229,"activeCount":10},[],{"intervention":218,"totalTrials":44,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":250},{"trials":233,"activeCount":10},[],{"trials":235,"activeCount":10},[],{"trials":237,"activeCount":10},[],{"trials":239,"activeCount":10},[],{"trials":241,"activeCount":10},[242,246],{"nctId":210,"briefTitle":211,"status":212,"phases":243,"primaryCompletion":214,"completion":214,"start":215,"enrollment":10,"conditions":244,"interventions":245},[39],[27],[197,218],{"nctId":220,"briefTitle":221,"status":81,"phases":247,"primaryCompletion":84,"completion":84,"start":223,"enrollment":224,"conditions":248,"interventions":249},[39],[27],[197,218,227],{"trials":251,"activeCount":10},[],{"intervention":253,"totalTrials":254,"cells":255},"Aripiprazole",1,{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":276},{"trials":257,"activeCount":10},[],{"trials":259,"activeCount":10},[],{"trials":261,"activeCount":10},[],{"trials":263,"activeCount":10},[],{"trials":265,"activeCount":10},[266],{"nctId":267,"briefTitle":268,"status":59,"phases":269,"completion":189,"start":270,"enrollment":224,"conditions":271,"interventions":275},"NCT00208169","Abilify Therapy for Reducing Comorbid Substance Abuse",[39],"2005-03",[31,154,272,273,274,155],"Bipolar Disorder","Major Depressive Disorder","Anxiety Disorders",[253],{"trials":277,"activeCount":10},[],{"intervention":279,"totalTrials":254,"cells":280},"Aspirin",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":301},{"trials":282,"activeCount":10},[],{"trials":284,"activeCount":10},[],{"trials":286,"activeCount":10},[],{"trials":288,"activeCount":10},[],{"trials":290,"activeCount":10},[291],{"nctId":292,"briefTitle":293,"status":59,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT00818337","Aspirin Responsiveness in Women at Risk for Cardiac Events",[39],"2009-06","2008-11",36,[299],"Heart Disease",[279],{"trials":302,"activeCount":10},[],{"intervention":67,"totalTrials":254,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":10},[],{"trials":308,"activeCount":10},[],{"trials":310,"activeCount":10},[],{"trials":312,"activeCount":10},[],{"trials":314,"activeCount":10},[315],{"nctId":57,"briefTitle":58,"status":59,"phases":316,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":317,"interventions":318},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":320,"activeCount":10},[],{"intervention":68,"totalTrials":254,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":10},[],{"trials":326,"activeCount":10},[],{"trials":328,"activeCount":10},[],{"trials":330,"activeCount":10},[],{"trials":332,"activeCount":10},[333],{"nctId":57,"briefTitle":58,"status":59,"phases":334,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":335,"interventions":336},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":338,"activeCount":10},[],{"intervention":69,"totalTrials":254,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":355},{"trials":342,"activeCount":10},[],{"trials":344,"activeCount":10},[],{"trials":346,"activeCount":10},[],{"trials":348,"activeCount":10},[],{"trials":350,"activeCount":10},[351],{"nctId":57,"briefTitle":58,"status":59,"phases":352,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":353,"interventions":354},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":356,"activeCount":10},[],{"intervention":70,"totalTrials":254,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":373},{"trials":360,"activeCount":10},[],{"trials":362,"activeCount":10},[],{"trials":364,"activeCount":10},[],{"trials":366,"activeCount":10},[],{"trials":368,"activeCount":10},[369],{"nctId":57,"briefTitle":58,"status":59,"phases":370,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":371,"interventions":372},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":374,"activeCount":10},[],{"intervention":71,"totalTrials":254,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":391},{"trials":378,"activeCount":10},[],{"trials":380,"activeCount":10},[],{"trials":382,"activeCount":10},[],{"trials":384,"activeCount":10},[],{"trials":386,"activeCount":10},[387],{"nctId":57,"briefTitle":58,"status":59,"phases":388,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":389,"interventions":390},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":392,"activeCount":10},[],{"intervention":72,"totalTrials":254,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":10},[],{"trials":398,"activeCount":10},[],{"trials":400,"activeCount":10},[],{"trials":402,"activeCount":10},[],{"trials":404,"activeCount":10},[405],{"nctId":57,"briefTitle":58,"status":59,"phases":406,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":407,"interventions":408},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":410,"activeCount":10},[],{"intervention":73,"totalTrials":254,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":427},{"trials":414,"activeCount":10},[],{"trials":416,"activeCount":10},[],{"trials":418,"activeCount":10},[],{"trials":420,"activeCount":10},[],{"trials":422,"activeCount":10},[423],{"nctId":57,"briefTitle":58,"status":59,"phases":424,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":425,"interventions":426},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":428,"activeCount":10},[],{"intervention":74,"totalTrials":254,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":445},{"trials":432,"activeCount":10},[],{"trials":434,"activeCount":10},[],{"trials":436,"activeCount":10},[],{"trials":438,"activeCount":10},[],{"trials":440,"activeCount":10},[441],{"nctId":57,"briefTitle":58,"status":59,"phases":442,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":443,"interventions":444},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":446,"activeCount":10},[],{"intervention":75,"totalTrials":254,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":463},{"trials":450,"activeCount":10},[],{"trials":452,"activeCount":10},[],{"trials":454,"activeCount":10},[],{"trials":456,"activeCount":10},[],{"trials":458,"activeCount":10},[459],{"nctId":57,"briefTitle":58,"status":59,"phases":460,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":461,"interventions":462},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":464,"activeCount":10},[],{"intervention":76,"totalTrials":254,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":10},[],{"trials":470,"activeCount":10},[],{"trials":472,"activeCount":10},[],{"trials":474,"activeCount":10},[],{"trials":476,"activeCount":10},[477],{"nctId":57,"briefTitle":58,"status":59,"phases":478,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":479,"interventions":480},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":482,"activeCount":10},[],{"intervention":77,"totalTrials":254,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":499},{"trials":486,"activeCount":10},[],{"trials":488,"activeCount":10},[],{"trials":490,"activeCount":10},[],{"trials":492,"activeCount":10},[],{"trials":494,"activeCount":10},[495],{"nctId":57,"briefTitle":58,"status":59,"phases":496,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":497,"interventions":498},[39],[27],[67,68,69,70,43,71,72,73,74,75,76,77],{"trials":500,"activeCount":10},[],{"intervention":502,"totalTrials":254,"cells":503},"Mometasone Furoate",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":523},{"trials":505,"activeCount":10},[],{"trials":507,"activeCount":10},[],{"trials":509,"activeCount":10},[],{"trials":511,"activeCount":10},[],{"trials":513,"activeCount":10},[514],{"nctId":515,"briefTitle":516,"status":59,"phases":517,"primaryCompletion":518,"completion":519,"start":63,"enrollment":520,"conditions":521,"interventions":522},"NCT00711165","Mometasone and Markers of Airway Inflammation",[39],"2006-04","2006-08",12,[22],[502],{"trials":524,"activeCount":10},[],{"intervention":526,"totalTrials":254,"cells":527},"Warfarin Dose based on pharmacogenetics",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":547},{"trials":529,"activeCount":10},[],{"trials":531,"activeCount":10},[],{"trials":533,"activeCount":10},[],{"trials":535,"activeCount":10},[],{"trials":537,"activeCount":10},[538],{"nctId":539,"briefTitle":540,"status":59,"phases":541,"primaryCompletion":296,"completion":296,"start":519,"enrollment":542,"conditions":543,"interventions":546},"NCT00511173","Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm",[39],102,[20,544,545],"Pulmonary Embolism","Deep Vein Thrombosis",[526],{"trials":548,"activeCount":10},[],{"intervention":550,"totalTrials":254,"cells":551},"Nicotine polacrilex",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":574},{"trials":553,"activeCount":10},[],{"trials":555,"activeCount":10},[],{"trials":557,"activeCount":10},[],{"trials":559,"activeCount":10},[],{"trials":561,"activeCount":10},[562],{"nctId":563,"briefTitle":564,"status":565,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":573},"NCT01925781","e-Cigarettes Versus NRT Gum for Smoking Cessation","TERMINATED",[39],"2013-11","2013-08",10,[571,572],"Nicotine Addiction","Smoking Cessation",[550],{"trials":575,"activeCount":10},[],{"intervention":577,"totalTrials":254,"cells":578},"Seroquel XR",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":600},{"trials":580,"activeCount":10},[],{"trials":582,"activeCount":10},[],{"trials":584,"activeCount":10},[],{"trials":586,"activeCount":10},[],{"trials":588,"activeCount":10},[589],{"nctId":590,"briefTitle":591,"status":59,"phases":592,"primaryCompletion":296,"completion":296,"start":593,"enrollment":85,"conditions":594,"interventions":599},"NCT00352469","Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety",[39],"2006-02",[595,274,596,29,597,598],"Alcoholism","Generalized Anxiety Disorder","Panic Disorder","Obsessive-Compulsive Disorder",[577],{"trials":601,"activeCount":10},[],{"intervention":603,"totalTrials":254,"cells":604},"Clopidogrel 75 mg\u002Fday",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":625},{"trials":606,"activeCount":10},[],{"trials":608,"activeCount":10},[],{"trials":610,"activeCount":10},[],{"trials":612,"activeCount":10},[],{"trials":614,"activeCount":10},[615],{"nctId":616,"briefTitle":617,"status":59,"phases":618,"primaryCompletion":619,"completion":619,"start":296,"enrollment":620,"conditions":621,"interventions":623},"NCT00817999","The Impact of Grapefruit Juice on the Response to Clopidogrel",[39],"2011-07",32,[622],"Healthy",[603,624],"Clopidogrel 300 mg",{"trials":626,"activeCount":10},[],{"intervention":624,"totalTrials":254,"cells":628},{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":637,"NA":643},{"trials":630,"activeCount":10},[],{"trials":632,"activeCount":10},[],{"trials":634,"activeCount":10},[],{"trials":636,"activeCount":10},[],{"trials":638,"activeCount":10},[639],{"nctId":616,"briefTitle":617,"status":59,"phases":640,"primaryCompletion":619,"completion":619,"start":296,"enrollment":620,"conditions":641,"interventions":642},[39],[622],[603,624],{"trials":644,"activeCount":10},[],{"intervention":646,"totalTrials":254,"cells":647},"Ziprasidone",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":669},{"trials":649,"activeCount":10},[],{"trials":651,"activeCount":10},[],{"trials":653,"activeCount":10},[],{"trials":655,"activeCount":10},[],{"trials":657,"activeCount":10},[658],{"nctId":659,"briefTitle":660,"status":59,"phases":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":668},"NCT00208208","Geodon (Ziprasidone) for Posttraumatic Stress Disorder",[39],"2005-04","2002-12",80,[666,29,667],"Posttraumatic Stress Disorder","PTSD",[646],{"trials":670,"activeCount":10},[],{"intervention":672,"totalTrials":254,"cells":673},"Lidocaine gel",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":695},{"trials":675,"activeCount":10},[],{"trials":677,"activeCount":10},[],{"trials":679,"activeCount":10},[],{"trials":681,"activeCount":10},[],{"trials":683,"activeCount":10},[684],{"nctId":685,"briefTitle":686,"status":81,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":693},"NCT02709304","Efficacy of Lidocaine Gel in Reducing Foley Catheter Discomfort in Surgical Patients",[39],"2017-01","2016-04",40,[692],"Urinary Catheter Discomfort in Surgical Patients",[672,694],"standard gel",{"trials":696,"activeCount":10},[],{"intervention":694,"totalTrials":254,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":713},{"trials":700,"activeCount":10},[],{"trials":702,"activeCount":10},[],{"trials":704,"activeCount":10},[],{"trials":706,"activeCount":10},[],{"trials":708,"activeCount":10},[709],{"nctId":685,"briefTitle":686,"status":81,"phases":710,"primaryCompletion":688,"completion":688,"start":689,"enrollment":690,"conditions":711,"interventions":712},[39],[692],[672,694],{"trials":714,"activeCount":10},[],{"intervention":227,"totalTrials":254,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":731},{"trials":718,"activeCount":10},[],{"trials":720,"activeCount":10},[],{"trials":722,"activeCount":10},[],{"trials":724,"activeCount":10},[],{"trials":726,"activeCount":10},[727],{"nctId":220,"briefTitle":221,"status":81,"phases":728,"primaryCompletion":84,"completion":84,"start":223,"enrollment":224,"conditions":729,"interventions":730},[39],[27],[197,218,227],{"trials":732,"activeCount":10},[],{"intervention":734,"totalTrials":254,"cells":735},"Plavix",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":754},{"trials":737,"activeCount":10},[],{"trials":739,"activeCount":10},[],{"trials":741,"activeCount":10},[],{"trials":743,"activeCount":10},[],{"trials":745,"activeCount":10},[746],{"nctId":747,"briefTitle":748,"status":212,"phases":749,"primaryCompletion":750,"completion":750,"start":108,"enrollment":10,"conditions":751,"interventions":753},"NCT00589862","Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents",[39],"2008-07",[752],"Coronary Artery Disease",[734],{"trials":755,"activeCount":10},[],{"intervention":757,"totalTrials":254,"cells":758},"Vancomycin 125 MG po BID",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":778},{"trials":760,"activeCount":10},[],{"trials":762,"activeCount":10},[],{"trials":764,"activeCount":10},[],{"trials":766,"activeCount":10},[],{"trials":768,"activeCount":10},[769],{"nctId":770,"briefTitle":771,"status":212,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":10,"conditions":775,"interventions":777},"NCT04241744","Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI",[39],"2020-01-13","2019-10-29",[776],"CDI",[757],{"trials":779,"activeCount":10},[],{"intervention":158,"totalTrials":254,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":796},{"trials":783,"activeCount":10},[],{"trials":785,"activeCount":10},[],{"trials":787,"activeCount":10},[],{"trials":789,"activeCount":10},[],{"trials":791,"activeCount":10},[792],{"nctId":148,"briefTitle":149,"status":59,"phases":793,"completion":151,"start":152,"enrollment":85,"conditions":794,"interventions":795},[39],[31,154,155,156],[158,127],{"trials":797,"activeCount":10},[],{"intervention":799,"totalTrials":254,"cells":800},"Topiramate",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":820},{"trials":802,"activeCount":10},[],{"trials":804,"activeCount":10},[],{"trials":806,"activeCount":10},[],{"trials":808,"activeCount":10},[],{"trials":810,"activeCount":10},[811],{"nctId":812,"briefTitle":813,"status":59,"phases":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT00208130","Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians",[39],"2004-03","2001-10",60,[29],[799],{"trials":821,"activeCount":10},[],{"intervention":823,"totalTrials":254,"cells":824},"Lithium Plus Extended- Release Carbamazepine",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":843},{"trials":826,"activeCount":10},[],{"trials":828,"activeCount":10},[],{"trials":830,"activeCount":10},[],{"trials":832,"activeCount":10},[],{"trials":834,"activeCount":10},[835],{"nctId":836,"briefTitle":837,"status":81,"phases":838,"completion":839,"start":840,"enrollment":85,"conditions":841,"interventions":842},"NCT00325286","Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder",[39],"2008-03","2006-05",[272],[823],{"trials":844,"activeCount":10},[],{"intervention":846,"totalTrials":254,"cells":847},"Fluoxetine",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":867},{"trials":849,"activeCount":10},[],{"trials":851,"activeCount":10},[],{"trials":853,"activeCount":10},[],{"trials":855,"activeCount":10},[],{"trials":857,"activeCount":10},[858],{"nctId":859,"briefTitle":860,"status":212,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":10,"conditions":864,"interventions":866},"NCT00573547","Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease",[39],"2008-08","2007-02",[865],"Depression",[846],{"trials":868,"activeCount":10},[],{"intervention":870,"totalTrials":254,"cells":871},"Divalproex ER",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":890},{"trials":873,"activeCount":10},[],{"trials":875,"activeCount":10},[],{"trials":877,"activeCount":10},[],{"trials":879,"activeCount":10},[],{"trials":881,"activeCount":10},[882],{"nctId":883,"briefTitle":884,"status":59,"phases":885,"completion":886,"start":815,"enrollment":85,"conditions":887,"interventions":889},"NCT00208195","Depakote ER Therapy for Mania Comorbid With Substance Abuse",[39],"2007-11",[272,888,155,156],"Mania",[870],{"trials":891,"activeCount":10},[],{"intervention":893,"totalTrials":254,"cells":894},"Atorvastatin 20 mg",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":916},{"trials":896,"activeCount":10},[],{"trials":898,"activeCount":10},[],{"trials":900,"activeCount":10},[],{"trials":902,"activeCount":10},[],{"trials":904,"activeCount":10},[905],{"nctId":906,"briefTitle":907,"status":81,"phases":908,"primaryCompletion":909,"completion":909,"start":568,"enrollment":910,"conditions":911,"interventions":914},"NCT02029534","Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)",[39],"2017-06",200,[912,913],"Cardiothoracic Surgery","Post-operative Atrial Fibrillation",[893,915],"Atorvastatin 80 mg",{"trials":917,"activeCount":10},[],{"intervention":915,"totalTrials":254,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":928,"NA":934},{"trials":921,"activeCount":10},[],{"trials":923,"activeCount":10},[],{"trials":925,"activeCount":10},[],{"trials":927,"activeCount":10},[],{"trials":929,"activeCount":10},[930],{"nctId":906,"briefTitle":907,"status":81,"phases":931,"primaryCompletion":909,"completion":909,"start":568,"enrollment":910,"conditions":932,"interventions":933},[39],[912,913],[893,915],{"trials":935,"activeCount":10},[],{"intervention":88,"totalTrials":254,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":952},{"trials":939,"activeCount":10},[],{"trials":941,"activeCount":10},[],{"trials":943,"activeCount":10},[],{"trials":945,"activeCount":10},[],{"trials":947,"activeCount":10},[948],{"nctId":79,"briefTitle":80,"status":81,"phases":949,"primaryCompletion":83,"completion":83,"start":84,"enrollment":85,"conditions":950,"interventions":951},[39],[20],[88,43],{"trials":953,"activeCount":10},[],{"intervention":955,"totalTrials":254,"cells":956},"rosiglitazone",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":958,"activeCount":10},[],{"trials":960,"activeCount":10},[],{"trials":962,"activeCount":10},[963],{"nctId":964,"briefTitle":965,"status":59,"phases":966,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":972},"NCT00614874","The Use of Rosiglitazone to Treat Asthma",[37],"2010-02","2010-03","2008-12",16,[22],[955],{"trials":974,"activeCount":10},[],{"trials":976,"activeCount":10},[],{"trials":978,"activeCount":10},[],{"intervention":980,"totalTrials":254,"cells":981},"Calcium carbonate",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":983,"activeCount":10},[],{"trials":985,"activeCount":10},[],{"trials":987,"activeCount":10},[988],{"nctId":989,"briefTitle":990,"status":59,"phases":991,"primaryCompletion":992,"completion":992,"start":143,"enrollment":993,"conditions":994,"interventions":996},"NCT00074711","Adding Phosphorus to Osteoporosis Drug Treatment",[37],"2008-06",241,[17,995],"Osteopenia",[980,997],"Calcium Phosphate",{"trials":999,"activeCount":10},[],{"trials":1001,"activeCount":10},[],{"trials":1003,"activeCount":10},[],{"intervention":997,"totalTrials":254,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1007,"activeCount":10},[],{"trials":1009,"activeCount":10},[],{"trials":1011,"activeCount":10},[1012],{"nctId":989,"briefTitle":990,"status":59,"phases":1013,"primaryCompletion":992,"completion":992,"start":143,"enrollment":993,"conditions":1014,"interventions":1015},[37],[17,995],[980,997],{"trials":1017,"activeCount":10},[],{"trials":1019,"activeCount":10},[],{"trials":1021,"activeCount":10},[],{"intervention":1023,"totalTrials":254,"cells":1024},"Calcium supplement",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1026,"activeCount":10},[],{"trials":1028,"activeCount":10},[],{"trials":1030,"activeCount":10},[1031],{"nctId":1032,"briefTitle":1033,"status":59,"phases":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1039},"NCT00000426","Treatment of Calcium Deficiency in Young Women",[37],"2000-06","1995-01",150,[17],[1023],{"trials":1041,"activeCount":10},[],{"trials":1043,"activeCount":10},[],{"trials":1045,"activeCount":10},[],{"intervention":1047,"totalTrials":254,"cells":1048},"Testosterone",{"EARLY_PHASE1":1049,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1072},{"trials":1050,"activeCount":10},[1051],{"nctId":1052,"briefTitle":1053,"status":59,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":520,"conditions":1058,"interventions":1063},"NCT01697345","Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",[35],"2013-04","2013-05","2013-02",[1059,1060,1061,1062],"Breast Cancer","Vaginal Dryness","Dyspareunia","Sexual Health Quality of Life",[1047],{"trials":1065,"activeCount":10},[],{"trials":1067,"activeCount":10},[],{"trials":1069,"activeCount":10},[],{"trials":1071,"activeCount":10},[],{"trials":1073,"activeCount":10},[],{"intervention":1075,"totalTrials":254,"cells":1076},"cholecalciferol\u002Fplacebo",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1078,"activeCount":10},[],{"trials":1080,"activeCount":10},[],{"trials":1082,"activeCount":10},[],{"trials":1084,"activeCount":10},[],{"trials":1086,"activeCount":10},[],{"trials":1088,"activeCount":10},[1089],{"nctId":1090,"briefTitle":1091,"status":565,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":967,"enrollment":25,"conditions":1094,"interventions":1096},"NCT01022398","Vitamin D Replacement: The Effect on Statin-Related Myalgias",[40],"2011-06",[1095],"HMG-CoA Reductase Inhibitors-related Myalgias",[1075],{"intervention":1098,"totalTrials":254,"cells":1099},"cholecalciferol.",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1101,"activeCount":10},[],{"trials":1103,"activeCount":10},[],{"trials":1105,"activeCount":10},[],{"trials":1107,"activeCount":10},[],{"trials":1109,"activeCount":10},[],{"trials":1111,"activeCount":10},[1112],{"nctId":1113,"briefTitle":1114,"status":59,"phases":1115,"primaryCompletion":109,"completion":109,"start":1116,"enrollment":690,"conditions":1117,"interventions":1118},"NCT00473239","The Pharmacokinetics of a Single Large Dose of Vitamin D3",[40],"2006-10",[14],[1098],{"intervention":1120,"totalTrials":254,"cells":1121},"D50 glucose",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1123,"activeCount":10},[],{"trials":1125,"activeCount":10},[],{"trials":1127,"activeCount":10},[],{"trials":1129,"activeCount":10},[],{"trials":1131,"activeCount":10},[],{"trials":1133,"activeCount":10},[1134],{"nctId":1135,"briefTitle":1136,"status":212,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":10,"conditions":1140,"interventions":1142},"NCT00643110","Milk as Treatment for Hypoglycemia",[40],"2009-01","2008-04",[1141],"Type 1 Diabetes",[1120],{"intervention":1144,"totalTrials":254,"cells":1145},"Eplerenone",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1147,"activeCount":10},[],{"trials":1149,"activeCount":10},[],{"trials":1151,"activeCount":10},[],{"trials":1153,"activeCount":10},[],{"trials":1155,"activeCount":10},[],{"trials":1157,"activeCount":10},[1158],{"nctId":1159,"briefTitle":1160,"status":565,"phases":1161,"primaryCompletion":117,"completion":117,"start":1162,"enrollment":85,"conditions":1163,"interventions":1165},"NCT00980031","Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension",[40],"2007-04",[1164],"Myocardial Remodeling",[1144,1166],"Lactose",{"intervention":1166,"totalTrials":254,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1170,"activeCount":10},[],{"trials":1172,"activeCount":10},[],{"trials":1174,"activeCount":10},[],{"trials":1176,"activeCount":10},[],{"trials":1178,"activeCount":10},[],{"trials":1180,"activeCount":10},[1181],{"nctId":1159,"briefTitle":1160,"status":565,"phases":1182,"primaryCompletion":117,"completion":117,"start":1162,"enrollment":85,"conditions":1183,"interventions":1184},[40],[1164],[1144,1166],{"intervention":1186,"totalTrials":254,"cells":1187},"DFDBA + Bio-Gide Membrane",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1189,"activeCount":10},[],{"trials":1191,"activeCount":10},[],{"trials":1193,"activeCount":10},[],{"trials":1195,"activeCount":10},[],{"trials":1197,"activeCount":10},[],{"trials":1199,"activeCount":10},[1200],{"nctId":1201,"briefTitle":1202,"status":212,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":10,"conditions":1206,"interventions":1208},"NCT01245920","Effects of Bone Graft Placement at Implant Installation on Buccal Plate Stability",[40],"2012-05","2010-11",[1207],"Peri-implant Alveolar Bone Thickness",[1186],{"intervention":1210,"totalTrials":254,"cells":1211},"Furosemide",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1220,"NA":1222},{"trials":1213,"activeCount":10},[],{"trials":1215,"activeCount":10},[],{"trials":1217,"activeCount":10},[],{"trials":1219,"activeCount":10},[],{"trials":1221,"activeCount":10},[],{"trials":1223,"activeCount":10},[1224],{"nctId":1225,"briefTitle":1226,"status":59,"phases":1227,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":1230,"conditions":1231,"interventions":1233},"NCT01584518","B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading",[40],"2013-06","2012-07",50,[1232],"Fluid Over-load",[1210],{"intervention":1235,"totalTrials":254,"cells":1236},"Nebivolol",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1238,"activeCount":10},[],{"trials":1240,"activeCount":10},[],{"trials":1242,"activeCount":10},[],{"trials":1244,"activeCount":10},[],{"trials":1246,"activeCount":10},[],{"trials":1248,"activeCount":10},[1249],{"nctId":1250,"briefTitle":1251,"status":212,"phases":1252,"primaryCompletion":1253,"completion":1253,"start":178,"enrollment":10,"conditions":1254,"interventions":1256},"NCT01051947","Impact of Nebivolol on Central Aortic Pressure",[40],"2010-05",[1255],"Central Aortic Pressure",[1235,1257],"Metoprolol",{"intervention":1257,"totalTrials":254,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1261,"activeCount":10},[],{"trials":1263,"activeCount":10},[],{"trials":1265,"activeCount":10},[],{"trials":1267,"activeCount":10},[],{"trials":1269,"activeCount":10},[],{"trials":1271,"activeCount":10},[1272],{"nctId":1250,"briefTitle":1251,"status":212,"phases":1273,"primaryCompletion":1253,"completion":1253,"start":178,"enrollment":10,"conditions":1274,"interventions":1275},[40],[1255],[1235,1257],{"intervention":1277,"totalTrials":254,"cells":1278},"Adding Advair Diskus 100\u002F50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":10},[],{"trials":1282,"activeCount":10},[],{"trials":1284,"activeCount":10},[],{"trials":1286,"activeCount":10},[],{"trials":1288,"activeCount":10},[],{"trials":1290,"activeCount":10},[1291],{"nctId":1292,"briefTitle":1293,"status":212,"phases":1294,"primaryCompletion":1162,"completion":1162,"start":518,"enrollment":10,"conditions":1295,"interventions":1297},"NCT00385463","Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo",[40],[22,1296],"Seasonal Allergic Rhinitis",[1277],{"intervention":1299,"totalTrials":254,"cells":1300},"Fluticasone",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1302,"activeCount":10},[],{"trials":1304,"activeCount":10},[],{"trials":1306,"activeCount":10},[],{"trials":1308,"activeCount":10},[],{"trials":1310,"activeCount":10},[],{"trials":1312,"activeCount":10},[1313],{"nctId":1314,"briefTitle":1315,"status":59,"phases":1316,"primaryCompletion":619,"completion":619,"start":1205,"enrollment":817,"conditions":1317,"interventions":1318},"NCT01240889","Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*",[40],[192],[1299,1319],"Fluticason",{"intervention":1319,"totalTrials":254,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1323,"activeCount":10},[],{"trials":1325,"activeCount":10},[],{"trials":1327,"activeCount":10},[],{"trials":1329,"activeCount":10},[],{"trials":1331,"activeCount":10},[],{"trials":1333,"activeCount":10},[1334],{"nctId":1314,"briefTitle":1315,"status":59,"phases":1335,"primaryCompletion":619,"completion":619,"start":1205,"enrollment":817,"conditions":1336,"interventions":1337},[40],[192],[1299,1319]]